映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09606 映恩生物-B

已收盘 07-24 16:08:05

234.200

-0.600

-0.26%

最高243.000	最低231.200	成交量57.17万
今开234.800	昨收234.800	日振幅5.03%
总市值212.05亿	流通市值212.05亿	总股本9,054万
成交额1.35亿	换手率0.63%	流通股本9,054万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":234.2,"timestamp":1784880485007,"preClose":234.8,"halted":0,"volume":571680,"delay":0,"changeRate":-0.0025553662691653435,"floatShares":90544200,"shares":90544200,"eps":-46.09925812067694,"marketStatus":"已收盘","change":-0.6,"latestTime":"07-24 16:08:05","open":234.8,"high":243,"low":231.2,"amount":134786267,"amplitude":0.050256,"askPrice":234.2,"askSize":3900,"bidPrice":234,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-36.916471226688834,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":5,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":234.8,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.485664,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606","defaultTab":"news","newsList":[{"id":"2653221532","title":"【券商聚焦】中国银河证券首予映恩生物(09606)推荐评级 指其ADC管线梯队完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2653221532","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653221532?lang=zh_cn&edition=full","pubTime":"2026-07-21 15:31","pubTimestamp":1784619085,"startTime":"0","endTime":"0","summary":"DB-1303安全性可控，HER2阳性乳腺癌已递交上市申请，填补HER2低表达患者治疗空白。DB-1310针对EGFR靶向耐药肺癌，多线人群ORR达43.5%。DB-1305联合双抗一线三阴性乳腺癌确认超高缓解率。创新管线中，全球首创自免ADC DB-2304靶向BDCA2，直击红斑狼疮未满足临床需求，已推进至IIa期。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986406","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","ADC","601881","KCE","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111245137","title":"异动解读｜映恩生物-B盘中下跌5.15%，报228.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111245137","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111245137?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:15","pubTimestamp":1784600144,"startTime":"0","endTime":"0","summary":"7月21日，映恩生物-B盘中下跌5.15%，报228.4港元/股，成交额5300.47万港元。映恩生物-B所在的生物科技行业整体走弱，个股中，百济神州跌2.19%，康方生物跌3.05%，信达生物跌2.49%，科伦博泰生物跌0.99%，三生制药跌2.24%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310等，公司主要在国内和国外市场开展业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652262259","title":"港股异动 | 映恩生物-B(09606.HK)午后涨近15% B7-H3 ADC拟纳入突破性疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2652262259","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652262259?lang=zh_cn&edition=full","pubTime":"2026-07-20 13:38","pubTimestamp":1784525921,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161","LU2543165471.USD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196132904","title":"异动解读｜映恩生物-B盘中上涨7.07%，DB-1310临床数据披露叠加合作方Avenzo完成纳斯达克上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1196132904","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196132904?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:32","pubTimestamp":1784514722,"startTime":"0","endTime":"0","summary":"7月20日，映恩生物-B盘中上涨7.07%，报230.2港元/股，成交额1.19亿港元。消息面上，公司近日在ASCO大会上以口头报告形式首次公布DB-1310用于治疗晚期实体瘤患者的I/IIa期试验初步结果，该品种此前已与阿斯利康就联合奥希替尼的临床探索达成合作。同时，合作方Avenzo于7月16日宣布通过反向合并实现纳斯达克上市，并完成2.15亿美元超额认购PIPE融资，其核心资产之一即为从映恩生物引进的EGFR/HER3双抗ADC DB-1418，进一步验证公司管线商业价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119752477","title":"异动解读｜映恩生物-B盘中下跌5.99%，报220.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119752477","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119752477?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:01","pubTimestamp":1784253660,"startTime":"0","endTime":"0","summary":"7月17日，映恩生物-B盘中下跌5.99%，报220.8港元/股，成交额5256.0万港元。映恩生物-B所在的生物科技行业整体走弱，个股中，康方生物跌7.71%，三生制药跌6.98%，科伦博泰生物跌4.65%，信达生物跌2.49%，百济神州跌2.15%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324等，公司主要在国内和国外市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06618","BK1161","06978","06622","BK1574","IBBQ","06996","03759","09688","02268","159992","09966","02269","02359","01672","01801","06606","02137","09995","03347","09606","00241","MEDX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1121533022","title":"异动解读｜映恩生物-B盘中上涨6.27%，东吴证券首予买入评级目标价418.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121533022","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121533022?lang=zh_cn&edition=full","pubTime":"2026-07-10 09:47","pubTimestamp":1783648050,"startTime":"0","endTime":"0","summary":"7月10日，映恩生物-B盘中上涨6.27%，报217.0港元/股，成交额3336.27万港元。消息面上，东吴证券近日首次覆盖映恩生物-B，给予\"买入\"评级，目标价418.61港元，较当前股价存在近90%的上行空间。映恩生物是一家全球性临床阶段生物制药公司，致力于研发抗体偶联药物创新疗法，核心候选药物包括DB-1303/BNT323、DB-1311/BNT324等，主要用于靶向治疗多种实体瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649965515","title":"【券商聚焦】东吴证券首予映恩生物(09606)买入评级 指核心管线疗效显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2649965515","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649965515?lang=zh_cn&edition=full","pubTime":"2026-07-08 15:14","pubTimestamp":1783494860,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券发布研报指，映恩生物-B 是一家专注于研发新一代ADC药物的全球领跑者，依托其自主研发的四大ADC技术平台，构建了覆盖HER2、B7-H3、HER3、TROP2等靶点的13条管线矩阵。研报观点聚焦于两款后期管线。公司已于2026年5月行使该产品美国市场共同开发与共同销售的选择权，有望深度参与并分享其海外商业化价值。东吴证券预计公司2026-2028年营业收入分别为20.52/23.95/25.99亿元，同比增速为10.8%/16.7%/8.5%。首次覆盖，给予“买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985367","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","601555","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117672089","title":"异动解读｜映恩生物-B盘中上涨5.33%，东吴证券首予买入评级目标价418.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117672089","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117672089?lang=zh_cn&edition=full","pubTime":"2026-07-08 10:00","pubTimestamp":1783476026,"startTime":"0","endTime":"0","summary":"7月8日，映恩生物-B盘中上涨5.33%，报222.0港元/股，成交额7281.16万港元。消息面上，东吴证券当日首次覆盖映恩生物-B，给予\"买入\"评级，目标价418.61港元，较当前股价存在近90%的上行空间。此外，公司科创板IPO审核状态已于近日变更为\"已问询\"，上市审核流程持续推进，叠加此前公司宣布最多4000万美元回购计划及DB-1311/BNT324全球Ⅲ期临床完成首例患者给药等利好，市场情绪偏暖。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649590309","title":"东吴证券：首予映恩生物(09606.HK)“买入”评级 目标价418.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649590309","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649590309?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:16","pubTimestamp":1783473398,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09606","BK1161","HK0000500386.USD","LU2543165471.USD","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195851382","title":"映恩生物-B发布6月股份变动月报，已发行股份增加68,600股","url":"https://stock-news.laohu8.com/highlight/detail?id=1195851382","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195851382?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:45","pubTimestamp":1783413932,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年7月7日公布截至2026年6月30日的股份变动月报，披露了公司在报告期内的股本结构及相关变动情况。本月公司法定股本未发生变化，维持在2亿股普通股，面值每股0.0001美元，对应注册股本2万美元。根据公告，映恩生物-B在6月内通过首次公开发售前股权激励计划有348,900股股份行权发行，获得行权资金2,361,829.50港元；当月还注销了12,081份股权激励期权，截至6月底该计划剩余18,089,549份期权。截至报告期末，映恩生物-B整体股本有所增加。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153580278","title":"异动解读｜映恩生物-B盘中下跌5.07%，报213.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153580278","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153580278?lang=zh_cn&edition=full","pubTime":"2026-07-07 15:18","pubTimestamp":1783408686,"startTime":"0","endTime":"0","summary":"7月7日，映恩生物-B盘中下跌5.07%，报213.4港元/股，成交额3.8亿港元。映恩生物-B所在的生物科技行业中，板块整体承压回调，个股中，三生制药跌7.2%，康方生物跌4.61%，信达生物跌4.14%，百济神州跌3.67%，科伦博泰生物跌2.87%。映恩生物是一家全球性临床阶段生物制药公司，致力于研发抗体偶联药物（ADC）创新疗法，核心候选药物包括DB-1303/BNT323、DB-1311/BNT324等，主要用于靶向治疗多种实体瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112923173","title":"异动解读｜映恩生物-B盘中上涨9.01%，科创板IPO审核状态变更为已问询叠加ADC赛道持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1112923173","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112923173?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:50","pubTimestamp":1783302612,"startTime":"0","endTime":"0","summary":"7月6日，映恩生物-B盘中上涨9.01%，报232.8港元/股，成交额9939.42万港元。消息面上，公司科创板IPO审核状态已于近日变更为\"已问询\"，标志着上市审核流程进一步推进，此前公司拟募资41亿元用于新药研发。此外，近期行业研报指出全球ADC市场预计于2032年突破千亿美元，中国企业竞争优势愈发显著，映恩生物作为ADC核心标的持续受到关注。行业层面，生物科技板块延续强势，荣昌生物涨4.67%，信达生物涨3.47%，三生制药涨2.4%，科伦博泰生物涨1.7%，康方生物涨1.07%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180831978","title":"异动解读｜映恩生物-B盘中上涨6.31%，ADC赛道集中突破叠加科创板IPO受理催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1180831978","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180831978?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:40","pubTimestamp":1783042855,"startTime":"0","endTime":"0","summary":"7月3日，映恩生物-B盘中上涨6.31%，报213.6港元/股，成交额9275.75万港元。消息面上，近期国产ADC赛道迎来集中突破，全球首款双抗ADC获批上市，中国企业领先优势显著；公司科创板IPO申请已获上交所受理，拟募资41亿元用于新药研发，双资本平台布局持续推进。行业层面，生物科技板块延续强势，三生制药涨4.85%，荣昌生物涨4.25%，康方生物涨2.69%，科伦博泰生物涨2.65%，信达生物涨2.4%，板块联动效应明显。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102162890","title":"异动解读｜映恩生物-B盘中上涨15.01%，ADC赛道迎集中突破叠加生物科技板块强势反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1102162890","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102162890?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:21","pubTimestamp":1782958881,"startTime":"0","endTime":"0","summary":"7月2日，映恩生物-B盘中上涨15.01%，报208.8港元/股，成交额2.09亿港元。消息面上，近期国产ADC赛道迎来集中突破，全球首款双抗ADC获批上市，中国企业领先优势显著，映恩生物科创板IPO申请已获上交所受理，拟募资41亿元用于新药研发，资本市场关注度提升。行业层面，生物科技板块今日整体走强，三生制药涨10.72%，康方生物涨8.74%，科伦博泰生物涨8.44%，信达生物涨8.04%，板块联动效应显著。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198082469","title":"异动解读｜映恩生物-B盘中上涨5.65%，回购护盘叠加生物科技板块反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1198082469","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198082469?lang=zh_cn&edition=full","pubTime":"2026-06-29 09:57","pubTimestamp":1782698221,"startTime":"0","endTime":"0","summary":"6月29日，映恩生物-B盘中上涨5.65%，报172.2港元/股，成交额2904.06万港元。消息面上，公司于6月26日斥资约1198.79万港元回购7.38万股，回购价介于161.2至164.4港元，显示管理层在股价低位积极护盘。此外，公司股东周年大会于6月26日通过新一轮回购授权，可回购股份总数达905.8万股，彰显对公司内在价值的信心。行业层面，生物科技板块今日整体回暖，药捷安康-B涨20.11%，荣昌生物涨6.25%，康方生物涨4.2%，百济神州涨1.63%，信达生物涨2.4%，板块联动效应明显。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647341995","title":"映恩生物-B(09606)6月26日斥资1198.79万港元回购7.38万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647341995","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647341995?lang=zh_cn&edition=full","pubTime":"2026-06-29 08:36","pubTimestamp":1782693366,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，该公司于2026年6月26日斥资1198.79万港元回购7.38万股股份，每股回购价格为161.2-164.4港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606","HK0000500386.USD","LU2543165471.USD","HK0000252160.HKD","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186149461","title":"映恩生物-B：6月26日回购73,800股，耗资约1,198.79万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186149461","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186149461?lang=zh_cn&edition=full","pubTime":"2026-06-29 08:21","pubTimestamp":1782692514,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年6月29日发布公告，披露于2026年6月26日于香港联交所场内回购73,800股普通股，占当日前已发行股本总数约0.0815%。本次回购价格介乎每股161.20港元至164.40港元，总金额约11,987,880港元。回购完成后，公司已发行股本总数维持在90,875,214股，库藏股数量增至400,100股。公告还显示，购回授权的决议于2026年6月26日获得通过，授权可回购的股份总数为9,058,021股。本次回购符合香港联合交易所有限公司证券上市规则等相关法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B：6月26日回购73,800股，耗资约1,198.79万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646736531","title":"映恩生物-B(09606.HK)：梁志杰已获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646736531","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646736531?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:26","pubTimestamp":1782484010,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09606","HK0000500386.USD","BK1161","LU2543165471.USD","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646365310","title":"映恩生物-B(09606)：梁志杰已获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646365310","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646365310?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:26","pubTimestamp":1782484010,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，曾颖雯女士(曾女士)已辞任本公司的联席公司秘书(联席公司秘书)、香港联合交易所有限公司(联交所)证券上市规则(上市规则)第3.05条项下的本公司授权代表(授权代表)及根据上市规则第19.05(2)条及《公司条例》(香港法例第622章)第16部所规定于香港代表本公司接收法律程序文件及通知之获授权代表(法律程序代理人)职务，自2026年6月26日起生效。梁志杰先生(梁先生)已获委任为联席公司秘书、授权代表及法律程序代理人以接替曾女士，自2026年6月26日起生效。袁佳丽女士(袁女士)将继续担任另一名联席公司秘书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","BK1161","09606","LU2543165471.USD","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":0.3273},{"period":"3month","weight":-0.1975},{"period":"6month","weight":-0.2983},{"period":"1year","weight":-0.2602},{"period":"ytd","weight":-0.2126}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":0.0803},{"period":"3month","weight":-0.0295},{"period":"6month","weight":-0.0575},{"period":"1year","weight":-0.0128},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}